MONDAY, Nov. 18, 2013 (HealthDay News) -- For patients with atherosclerotic renal-artery stenosis and hypertension or chronic kidney disease, renal-artery stenting confers no significant benefit as an addition to comprehensive medical therapy, according to a study published online Nov. 18 in the New England Journal of Medicine. The research was published to coincide with the American Heart Association's 2013 Scientific Sessions, held from Nov. 16 to 19 in Dallas.
Christopher J. Cooper, M.D., from the University of Toledo in Ohio, and colleagues randomized 947 participants with atherosclerotic renal-artery stenosis and systolic hypertension while taking two or more antihypertensive agents or chronic kidney disease to receive medical therapy plus renal-artery stenting or medical therapy alone. Participants were followed for a median of 43 months for the occurrence of adverse cardiovascular and renal events.
The researchers found that there was no significant difference between the groups in the rate of the primary composite end point (35.1 percent for medical therapy plus stenting versus 35.8 percent for medical therapy alone; P = 0.58). The rates of the individual components of the primary end point or all-cause mortality also did not differ significantly between the groups. There was a consistent modest difference in systolic blood pressure favoring the stent group during follow-up (−2.3 mm Hg; P = 0.03).
"Renal-artery stenting did not confer a significant benefit with respect to the prevention of clinical events when added to comprehensive, multifactorial medical therapy in people with atherosclerotic renal-artery stenosis and hypertension or chronic kidney disease," the authors write.
Several authors disclosed financial ties to the pharmaceutical and biotechnology industries.
Abstract
Full Text
Editorial
More Information
